FDA loses leadership and top reviewers

Summary

Following DOGE-directed layoffs of ~1,000 probationary FDA employees in February 2025 and a larger 3,500-position cut announced March 27, 2025, the FDA lost critical review capacity. Top vaccine regulator Dr. Peter Marks resigned April 5, 2025, citing RFK Jr.'s promotion of misinformation. Remaining reviewers were assigned double workloads.

What happened

DOGE fired approximately 1,000 probationary FDA employees in February 2025, targeting tobacco, food, and medical device centers before some were rehired. The March 27 restructuring eliminated 3,500 more FDA positions (of ~18,000 total), a 19% workforce reduction. FDA scientists reported being assigned roughly double the number of new product-application reviews after colleagues were terminated, while also being instructed to shelve supervisory and early-feedback work. This raised expert concerns about slower reviews or missed red flags in product applications. Dr. Peter Marks, who had led CBER since 2016 and oversaw COVID-19 vaccine approval, resigned April 5, 2025, writing that RFK Jr. preferred "subservient confirmation of his misinformation and lies" over scientific integrity. The FDA's overall leadership drain - including departures of other senior officials - generated widespread concern about the agency's ability to fulfill its statutory review obligations.

Impact on the United States

Drug and device review deadlines at risk of being missed; vaccine regulatory expertise lost at a critical time; reduced safety oversight of biologics, gene therapies, and food supply.

Documented effects

1. Mar 2025FDA device and tobacco-product reviewers handling roughly double application loads as of March 27, 2025[1]
2. Apr 2025Peter Marks (CBER Director since 2016) resigned April 5, 2025, citing Kennedy's promotion of "misinformation and lies"[2]
3. Mar 2025FDA announced 3,500-position cut March 27, 2025, on top of earlier DOGE layoffs[3]

Why this is rated severe

The loss of about 1,000 probationary staff, a further 3,500-position cut and the departure of the top vaccine regulator left some reviewers with roughly double workloads, putting drug, device and vaccine review capacity at risk.

Corrections & updates [7]

Every change to a fact on this page after publication is logged here, newest first.

1. Sep 29, 2026CorrectedFigures

   The cited Reuters report says the FDA had more than 20,000 workers earlier in 2025; the "~18,000 total" and "19% reduction" figures are not supported by any cited source. The reviewers who described double workloads were medical-device and tobacco-product reviewers, and the experts' concern was about missed "red flags" in product applications generally, not drug applications specifically.[1]

2. Sep 29, 2026ClarifiedSource

   BioPharma Dive is a specialist trade publication (Tier 3); its article was published March 29, 2025.[2]

3. Sep 29, 2026CorrectedSummary card

   The summary card said the 3,500-position cut left reviewers with double workloads. Reuters reported the doubled review loads on March 27, 2025, after the February layoffs and before the 3,500-position cut announced that day took effect. It also said Peter Marks resigned 'in protest'; he resigned citing Kennedy's promotion of 'misinformation and lies.' The card now matches the sources.[1][2][3]

4. Sep 29, 2026ClarifiedSeverity rationale

   Replaced 'compromised' with the record's wording. Severity unchanged.

   + Show previous and current text- Hide previous and current text

   Previously

   Loss of top reviewers and leadership compromised drug, device, and vaccine oversight, a severe realized degradation of US safety review capacity.

   Now

   The loss of about 1,000 probationary staff, a further 3,500-position cut and the departure of the top vaccine regulator left some reviewers with roughly double workloads, putting drug, device and vaccine review capacity at risk.

5. Sep 29, 2026CorrectedDisplay copy

   A key fact said FDA reviewers generally had double loads; the record says device and tobacco-product reviewers reported roughly double loads.[1]

   Previously

   FDA reviewers handling double application loads

   Now

   Some FDA reviewers handling roughly double application loads

6. Sep 29, 2026ClarifiedSource labels

   Source tier labels brought in line with the site's tier rule (specialist and trade publications are Tier 3; general news organizations are Tier 2): STAT News (Tier 2 to 3). No claim in the entry changed.

7. Sep 29, 2026CorrectedCost estimate

   The booked cost, the federal run-rate and the broader cost were all unsourced estimates (the block itself said no independent quantification exists). The '~4,500 positions lost' figure also ignored rehires. Nothing is booked. That is a floor, not a finding of no harm.

   Previously

   net $150M so far; 10yr $400M; 15yr $550M; broader $1B

   Now

   net $0; 10yr $0; 15yr $0; broader $0

Sources [3]